301290 Jiangsu Canopus Wisdom Medical Technology
- 22.66
- +0.27+1.21%
Jiangsu Canopus Wisdom Medical Technology News
Dongxing Healthcare (301290.SZ) announced first-quarter results, net profit of 19.897 million yuan, an increase of 10.56%
Dongxing Healthcare (301290.SZ) released its report for the first quarter of 2024. The company's revenue was 9181...
Dongxing Medical (301290.SZ): The product does not currently involve artificial intelligence technology
Gelonghui March 22丨An investor asked Dongxing Healthcare (301290.SZ) on the investor interactive platform, “Does the company's products use artificial intelligence technology?” The company replied that the company's products do not currently involve artificial intelligence technology.
Dongxing Medical (301290.SZ): Product target overseas markets are mainly concentrated in the three major regions of South America, the Middle East and Europe
Gelonghui March 12 丨 Some investors asked Dongxing Healthcare (301290.SZ) on the investor interactive platform, “Does the company have related business in the US? Are there plans to launch and develop Ar-related products?” The company replied that many of the company's products have been certified by the US FDA, Brazil's ANVISA, and South Korea's KFDA according to the different medical device regulatory policies or practices of different overseas countries or regions. The company's target overseas markets are mainly concentrated in the three major regions of South America, the Middle East and Europe. The company will strive to expand overseas markets and increase its market share.
Dongxing Healthcare (301290.SZ): As of March 8, 2024, the total number of shareholders of the company was 12,461
Gelonghui March 11 | Dongxing Medical (301290.SZ) said on the investor interactive platform that as of March 8, 2024, the total number of shareholders of the company was 12,461 (including credit accounts).
Dongxing Medical (301290.SZ): At present, the company's endoscopic staplers have entered more than 300 domestic hospitals, mainly in the top three hospitals
Gelonghui March 8 | Dongxing Medical (301290.SZ) said on the investor interactive platform that at present, the company's endoscopic staplers have entered more than 300 domestic hospitals, mainly in the top three hospitals.
Dongxing Medical (301290.SZ): A total cost of 24.983,200 yuan to buy back 1.23% of the shares
Gelonghui, March 5, 丨 Dongxing Medical (301290.SZ) announced that as of February 29, 2024, the total number of shares repurchased by the company through centralized bidding transactions through a special stock repurchase account was 1,235,051 shares, accounting for 1.23% of the company's current total share capital. The highest transaction price was 21.70 yuan/share, the minimum transaction price was 17.09 yuan/share, and the total transaction amount was 24.9832 million yuan (excluding transaction fees).
Dongxing Medical (301290.SZ): The surgical robot project is still in early planning
Gelonghui Feb. 28 | Dongxing Medical (301290.SZ) said on the investor interactive platform that currently the company's R&D focus is mainly on industry-forward-looking products such as electric endoscopic staplers and ultrasound knives. The surgical robot project is still in early planning.
Dongxing Medical (301290.SZ): 1.23% of shares have been repurchased cumulatively
Gelonghui, Feb. 21丨Dongxing Medical (301290.SZ) announced that as of February 19, 2024, the total number of shares repurchased by the company through centralized bidding transactions through a special stock repurchase account was 1,235,051 shares, accounting for 1.23% of the company's current total share capital. The highest transaction price was 21.70 yuan/share, the minimum transaction price was 17.09 yuan/share, and the total transaction amount was 249.832 million yuan (excluding transaction fees).
Dongxing Healthcare (301290.SZ): Initial repurchase of 51,500 shares involving 898,800 yuan
Gelonghui, Feb. 7 | Dongxing Medical (301290.SZ) announced that on February 7, 2024, for the first time, the company repurchased 514.79 million shares of the company through a dedicated stock repurchase securities account, accounting for 0.05% of the company's current total share capital. The highest transaction price was 17.50 yuan/share, the lowest transaction price was 17.09 yuan/share, and the total transaction amount was 898,800 yuan (excluding transaction fees).
Dongxing Medical (301290.SZ): Plans to spend 20 million yuan to 30 million yuan to buy back the company's shares
Gelonghui, Feb. 5 | Dongxing Medical (301290.SZ) announced that the company plans to use its own funds to repurchase the company's shares through centralized bidding transactions. The types of shares the company will repurchase are RMB common stock (A shares) shares already issued and listed by the company, which will be used to implement equity incentives or employee stock ownership plans. The total repurchase capital is not less than RMB 20 million (inclusive) and not more than RMB 30 million (inclusive). The price of the repurchase of shares: no more than RMB 37.00 per share (inclusive). The period for the repurchase of shares: the review and approval of the share repurchase plan by the board of directors of the company
Dongxing Medical (301290.SZ): Plans to subscribe for Hetang Phase II Health Fund's share of 10 million yuan
Gelonghui, Feb. 2: Dongxing Medical (301290.SZ) announced that in order to promote the long-term development of the company, make full use of the resource advantages of professional investment institutions to further broaden the company's industry sector and enhance the company's overall competitiveness, without affecting the daily operation and development of the company and effectively controlling investment risks, Jiangsu Dongxing Smart Medical Technology Co., Ltd. (the “Company” for short) will invest 10 million yuan in its own capital to subscribe to Beijing Hetang Phase II Health Venture Investment Partnership (limited partnership) (hereinafter referred to as “Hetang Phase II Health Fund” or “partnership”) share and become this partnership
Investors Don't See Light At End Of Jiangsu Canopus Wisdom Medical Technology Co.,Ltd.'s (SZSE:301290) Tunnel And Push Stock Down 26%
To the annoyance of some shareholders, Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. (SZSE:301290) shares are down a considerable 26% in the last month, which continues a horrid run for the compa
Dongxing Healthcare (301290.SZ) received a warning letter from the Jiangsu Securities Regulatory Bureau
Dongxing Healthcare (301290.SZ) announced that the company recently received an announcement from the China Securities Regulatory Commission and the Jiangsu Regulatory Bureau...
Dongxing Healthcare (301290.SZ): As of December 29, 2023, the total number of shareholders of the company was 13,295
Gelonghui January 4 | Dongxing Medical (301290.SZ) said on the investor interactive platform that as of December 29, 2023, the total number of shareholders of the company was 13,295.
Dongxing Healthcare (301290.SZ): Dongxing Huamei plans to acquire 40% of Mitutoyo Dongxing's shares for 11.138 million yuan
Glonghui December 18丨Dongxing Healthcare (301290.SZ) announced that the company held a general manager's office meeting on December 15, 2023, and agreed that Dongxing Huamei Medical Technology (Changzhou) Co., Ltd. (“Dongxing Huamei”), a wholly-owned subsidiary of the company, will acquire its holding subsidiary Mitutoyo Dongxing Medical Devices (Jiangsu) Co., Ltd. (“Sanfeng Dongxing” or “joint venture”) with its own capital of 11.138 million yuan to acquire its holding subsidiary Mitutoyo Medical Devices (Jiangsu) Co., Ltd. (“Sanfeng Dongxing” or “joint venture”) minority shareholder Benji Mitutoyo Medical Devices Co., Ltd. (“BenQ” or “counterparty”) 40% of the shares held. After this acquisition is completed, Mitoyo Dongxing will become
Dongxing Healthcare (301,290.SZ) will list 44.0886 million restricted shares for circulation starting December 1
Dongxing Medical (301290.SZ) issued an announcement. The shares whose sale restrictions have been lifted this time are before some of the company's initial public offerings...
Dongxing Medical (301290.SZ): The product under development, the ultrasonic knife system is a supporting product for soft tissue cutting, hemostasis, plastic surgery, etc.
Gelonghui November 15 | Dongxing Medical (301290.SZ) stated on the investor interactive platform that the company's disposable fully electric endoscopic cutting stapler is based on the design and development of the fully electric endoscopic stapler and its components based on existing electric endoscopic stapler products, and is equipped with related electric firing, steering, swing and automatic component recognition systems to achieve full electrification of the stapler. The company uses a design scheme where the cutter is placed in the nail box component to avoid passivation after the cutter is used many times; using an advanced intelligent stitch length recognition system, after the nail box component is assembled, the stapler intelligently recognizes the stitch length of the nail box component
[BT Financial Report Instantaneous Analysis] Dongxing Medical's 2023 Quarterly Report: Balance ratio declined, net cash flow increased significantly
This financial report was announced on 2023-10-24 18:26:56. Dongxing Medical (stock code: 301290) is a company focusing on R&D, production and sales of surgical medical devices. The company's main products include staplers and their components, surgical equipment, and medical device products sold by agents. In terms of assets and liabilities, at the end of the third quarter of 2023, Dongxing Medical's total assets were 2,368 billion yuan, a slight decrease from 2,384 billion yuan at the end of the previous year. Total liabilities were $139 million, a decrease of 22.78% from $180 million at the end of the previous year, with negative assets
Dongxing Medical (301290.SZ) released results for the first three quarters, with net profit of 71.412,600 yuan, a year-on-year decrease of 7.23%
Dongxing Medical (301290.SZ) released its report for the third quarter of 2023. The company achieved operating income in the first three quarters...
Dongxing Medical (301290.SZ): It is a strong competitor and high-quality substitute for imported products in the stapler industry
GLONGHUI, September 20 | Dongxing Medical (301290.SZ) said on the investor interactive platform that in recent years, with the continuous advancement of procurement of staplers, the quality of domestic manufacturers has steadily improved, and import substitution of stapler products has gradually accelerated. According to Frost & Sullivan analysis, from 2020 to 2022, the localization rate of manual endoscopic staplers in China increased from 26% to 41%, and the localization rate of electric mirror staplers in China increased from 7% to 22%. The process of localization of endoscopic staplers in China has accelerated markedly. The company is a strong competitor and high-quality replacement for imported products in the stapler industry.
Analysis
Price Target
No Data
